Use of bisphosphonates in skeletal metastasis

Acta Oncologica

Volumn 39, Issue 4, 2000, Pages 445-454

  Elomaa, Inkeri ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; UNCLASSIFIED DRUG; WY 47766; ZOLENDRONATE;

ANALGESIA; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EPISCLERITIS; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; HYPERCALCEMIA; MULTIPLE MYELOMA; OSTEOLYSIS; OSTEOMALACIA; PATHOLOGIC FRACTURE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SCLERITIS; UVEITIS;

EID: 0033804521     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418600750013357     Document Type: Review

References (65)

1. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review
2. Current use of bisphophonates in oncology
3. Clodronate. A review of its use in breast cancer
4. An update of clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy
5. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
6. Characteristics of clodronate induced apoptosis in osteoclasts and macrophages
7. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide independent mechanism
8. Apoptosis in phagocytotic cells of lymphoid tissue in rainbow trout (Oncorhynhus mykiss) following administration of clodronate liposomes
9. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumor activity
10. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases
11. Diphosphonates for osteolytic metastases
12. Treatment of skeletal disease in breast cancer: A controlled clodronate trial
13. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with metastasizing to the skeleton
14. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
15. Palliative pamidronate treatment in patients with bone metastases from breast cancer
16. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial
17. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
18. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
19. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lyric bone lesions: A randomized, placebo-controlled trial
20. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
21. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
22. No reduction of bone metastases with adjuvant clodronate treatment in node positive breast cancer patients
23. Adjuvant clodronate reduces the incidence of bone metastases in patients with operable breast cancer
24. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?
25. Spinal and femoral bone mineral density in women with breast cancer: Effect of clodronate therapy
26. Chemical castration induced by adjuvant CMF therapy causes a rapid bone loss which is reduced by clodronate. A randomized study in premenopausal breast cancer women
27. Clodronate improves bone mineral density in postmenopausal breast cancer women treated with adjuvant antiestrogens
28. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer
29. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study
30. Effect of daily etidronate on the osteolysis of multiple myeloma
31. Long-term effects of parenteral dichlorodimethylene bisphosphonate (C2MBP) on bone disease of myeloma patients treated with chemotherapy
32. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment - A multicenter study
33. Randomized placebo-controlled multicentre trial of clodronate in multiple myeloma
34. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma
35. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
36. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
37. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
38. Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of a randomized, prospective double-blinded, placebo-controlled study
39. Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostate cancer. Preliminary report
40. Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group
41. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma
42. Response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy and biochemical markers of bone metabolism
43. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma
44. A randomized double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy
45. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases
46. Double-blind, placebo-controlled, dose response trial of oral clodronate in patients with bone metastases
47. Effect of oral clodronate on metastatic bone pain: A double-blind, placebo-controlled study
48. A double-blind cross-over trial of IV clodronate in metastatatic bone pain
49. Double-blind randomized trial of pamidronate for palliative treatment of metastastic bone disease
50. Progression of bone metastases in breast cancer patients receiving pamidronate
51. Oral bisphosphonates. A review of clinical use in patients with bone metastases
52. Pharmacokinetics of clodronate in patients with metastatic breast cancer
53. Pooling of clodronate urinary excretion data: A new pharmacokinetic method to study drugs with highly variable gastrointestinal absorption
54. Patient preference for oral versus intravenous palliative chemotherapy
55. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone
56. Economic assessment of clodronate in the preventive treatment of bone resorption in patients with metastatic breast cancer
57. Economic impact of using clodronate in the management of patients with multiple myeloma
58. Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis
59. Severe hypocalcaemia after treatment of diphosphonate and aminoglycoside. Correspondence
60. Severe hypocalcaemia after treatment with oral clodronate and aminoglycoside. Correspondence
61. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease
62. Mineralisation defects with pamidronate therapy for Paget's disease
63. Renal failure associated with intravenous diphosphonates